E

Could Targeting Regulatory T cells be a game changer?

Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.

March 18, 2019
E

Where are the next Immuno-Oncology breakthroughs coming from?

In order to generate more IO therapies, we first need to get a better grip on the underlying biology.

March 13, 2019
E

Defense is the Best Attack – Part 1

Update on T cell bispecifics and other key topics in early stage IO development

March 12, 2019
E

Why did Atezolizumab fail in advanced Urothelial Bladder Cancer?

Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.

June 27, 2017
E

EACR17 Cancer Genomics Day 3

Notes on HGSOC, melanoma resistance and the evolution of NSCLC...

June 29, 2017
E
Punting on River Cam, Cambridge

EACR Cancer Genomics Day 2

Coverage of European Association for Cancer Research EACR cancer genomics conference at Churchill College, Cambridge

June 28, 2017
E

EACR Cancer Genomics Day 1 Update #CG17

Commentary from Day 1-2 of the 3rd EACR meeting on Cancer Genomics

June 27, 2017